M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers

Not Applicable

Completed

Conditions: Skin Cancer

Interventions: Procedure: Optical Imaging

First Posted Date: 2007-02-07

Last Posted Date: 2017-06-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00432471

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma

Phase 2

Terminated

Conditions: Retinoblastoma

Interventions: Radiation: Proton Beam Radiation Therapy
Procedure: Ophthalmic EUA

First Posted Date: 2007-02-07

Last Posted Date: 2015-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00432445

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Perifosine
Drug: Docetaxel

First Posted Date: 2007-02-05

Last Posted Date: 2016-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00431054

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Development of the MDASI-Spine Tumor Module

Completed

Conditions: Spinal Cord Tumor

Interventions: Behavioral: Survey

First Posted Date: 2007-02-02

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 128

Registration Number: NCT00430872

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin

Not Applicable

Withdrawn

Conditions: Liver Cancer
Liver Metastasis

Interventions: Procedure: Electro-Stimulation of Yongquan (K1) Acupoint

First Posted Date: 2007-02-01

Last Posted Date: 2023-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00430313

Study of Atiprimod Treatment for Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: Atiprimod

First Posted Date: 2007-02-01

Last Posted Date: 2012-02-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00430014

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Acupuncture for Prevention of Radiation-Induced Xerostomia

Not Applicable

Completed

Conditions: Xerostomia
Nasopharyngeal Cancer
Mouth Dryness

Interventions: Other: Standard Care
Procedure: Acupuncture

First Posted Date: 2007-02-01

Last Posted Date: 2021-06-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00430378

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

Phase 2

Completed

Conditions: Breast Cancer
Bone Metastases

Interventions: Drug: 153 Sm-EDTMP
Behavioral: Questionnaire
Procedure: Stem Cell Transplant

First Posted Date: 2007-01-31

Last Posted Date: 2015-11-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00429507

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Metastatic Breast Carcinoma
Invasive Breast Carcinoma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Stem Cell Transplant

First Posted Date: 2007-01-31

Last Posted Date: 2013-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00429182

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Dasatinib in Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer
Solid Tumors

Interventions: Drug: Dasatinib
Drug: Gemcitabine

First Posted Date: 2007-01-31

Last Posted Date: 2013-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 54

Registration Number: NCT00429234

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy